<?xml version='1.0' encoding='utf-8'?>
<document id="30566691"><sentence text="Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling."><entity charOffset="42-52" id="DDI-PubMed.30566691.s1.e0" text="Rifampicin" /><entity charOffset="69-81" id="DDI-PubMed.30566691.s1.e1" text="Cabotegravir" /><entity charOffset="86-97" id="DDI-PubMed.30566691.s1.e2" text="Rilpivirine" /><pair ddi="false" e1="DDI-PubMed.30566691.s1.e0" e2="DDI-PubMed.30566691.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s1.e0" e2="DDI-PubMed.30566691.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s1.e0" e2="DDI-PubMed.30566691.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30566691.s1.e1" e2="DDI-PubMed.30566691.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s1.e1" e2="DDI-PubMed.30566691.s1.e2" /></sentence><sentence text="Cabotegravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administered intramuscularly; their interaction with rifampicin, a first-line antituberculosis agent, has not been investigated"><entity charOffset="0-12" id="DDI-PubMed.30566691.s2.e0" text="Cabotegravir" /><entity charOffset="17-28" id="DDI-PubMed.30566691.s2.e1" text="rilpivirine" /><entity charOffset="133-143" id="DDI-PubMed.30566691.s2.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30566691.s2.e0" e2="DDI-PubMed.30566691.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s2.e0" e2="DDI-PubMed.30566691.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s2.e0" e2="DDI-PubMed.30566691.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30566691.s2.e1" e2="DDI-PubMed.30566691.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s2.e1" e2="DDI-PubMed.30566691.s2.e2" /></sentence><sentence text=" The aim of this study was to simulate and predict drug-drug interactions (DDIs) between these LA antiretroviral agents and rifampicin using physiologically based pharmacokinetic (PBPK) modeling"><entity charOffset="124-134" id="DDI-PubMed.30566691.s3.e0" text="rifampicin" /></sentence><sentence text="" /><sentence text="The designed PBPK models were qualified (according to European Medicines Agency guidelines) against observed data for oral formulations of cabotegravir, rilpivirine, and rifampicin"><entity charOffset="139-151" id="DDI-PubMed.30566691.s5.e0" text="cabotegravir" /><entity charOffset="153-164" id="DDI-PubMed.30566691.s5.e1" text="rilpivirine" /><entity charOffset="170-180" id="DDI-PubMed.30566691.s5.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30566691.s5.e0" e2="DDI-PubMed.30566691.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s5.e0" e2="DDI-PubMed.30566691.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s5.e0" e2="DDI-PubMed.30566691.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30566691.s5.e1" e2="DDI-PubMed.30566691.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s5.e1" e2="DDI-PubMed.30566691.s5.e2" /></sentence><sentence text=" Induction potential of rifampicin was also qualified by comparing the DDI between oral cabotegravir and oral rilpivirine with rifampicin"><entity charOffset="24-34" id="DDI-PubMed.30566691.s6.e0" text="rifampicin" /><entity charOffset="88-100" id="DDI-PubMed.30566691.s6.e1" text="cabotegravir" /><entity charOffset="110-121" id="DDI-PubMed.30566691.s6.e2" text="rilpivirine" /><entity charOffset="127-137" id="DDI-PubMed.30566691.s6.e3" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e0" e2="DDI-PubMed.30566691.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e0" e2="DDI-PubMed.30566691.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e0" e2="DDI-PubMed.30566691.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e0" e2="DDI-PubMed.30566691.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e1" e2="DDI-PubMed.30566691.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e1" e2="DDI-PubMed.30566691.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e1" e2="DDI-PubMed.30566691.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e2" e2="DDI-PubMed.30566691.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30566691.s6.e2" e2="DDI-PubMed.30566691.s6.e3" /></sentence><sentence text=" Qualified PBPK models were utilized for pharmacokinetic prediction of DDIs" /><sentence text="" /><sentence text="PBPK models predicted a reduction in both area under the curve (AUC0-28 days) and trough concentration (Ctrough, 28th day) of LA cabotegravir of 41%-46% for the first maintenance dose coadministered with 600 mg once-daily oral rifampicin"><entity charOffset="227-237" id="DDI-PubMed.30566691.s9.e0" text="rifampicin" /></sentence><sentence text=" Rilpivirine concentrations were predicted to decrease by 82% for both AUC0-28 days and Ctrough, 28th day following the first maintenance dose when coadministered with rifampicin"><entity charOffset="1-12" id="DDI-PubMed.30566691.s10.e0" text="Rilpivirine" /><entity charOffset="168-178" id="DDI-PubMed.30566691.s10.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30566691.s10.e0" e2="DDI-PubMed.30566691.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s10.e0" e2="DDI-PubMed.30566691.s10.e1" /></sentence><sentence text="" /><sentence text="The developed PBPK models predicted the theoretical effect of rifampicin on cabotegravir and rilpivirine LA intramuscular formulations"><entity charOffset="62-72" id="DDI-PubMed.30566691.s12.e0" text="rifampicin" /><entity charOffset="76-88" id="DDI-PubMed.30566691.s12.e1" text="cabotegravir" /><pair ddi="false" e1="DDI-PubMed.30566691.s12.e0" e2="DDI-PubMed.30566691.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s12.e0" e2="DDI-PubMed.30566691.s12.e1" /></sentence><sentence text=" According to these simulations, it is likely that coadministration of rifampicin with these LA formulations will result in subtherapeutic concentrations of both drugs"><entity charOffset="71-81" id="DDI-PubMed.30566691.s13.e0" text="rifampicin" /><entity charOffset="93-95" id="DDI-PubMed.30566691.s13.e1" text="LA" /><pair ddi="false" e1="DDI-PubMed.30566691.s13.e0" e2="DDI-PubMed.30566691.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30566691.s13.e0" e2="DDI-PubMed.30566691.s13.e1" /></sentence><sentence text="" /></document>